Pharmacology and mechanisms of action of new oral anticoagulants.

Joe-Elie Salem, Pierre Sabouret, Christian Funck-Brentano, Jean-Sebastien Hulot

Journal: Fundamental & clinical pharmacology 2015;29(1):10-20

PMID: 25196680

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

The new oral anticoagulants are announced as an important therapeutic revolution, particularly after their approval by authorities for stroke prevention in atrial fibrillation. However, the pharmacology of these new drugs is not homogeneous. In this review, we summarize the main pharmacological characteristics of the new direct anti-Xa and anti-IIa agents.

Address: Department of Pharmacology and UMR ICAN 1166, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Universités, UPMC Univ Paris 06, F-75013, Paris, France; Department of Pharmacology and CIC-1421, Institute of Cardiometabolism and Nutrition (ICAN), AP-HP, Pitié-Salpêtrière Hospital, F-75013, Paris, France; INSERM, Institute of Cardiometabolism and Nutrition (ICAN), CIC-1421 and UMR ICAN 1166, F-75013, Paris, France.

DOI: 10.1111/fcp.12091

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Other Literature Sources:

https://scite.ai/reports/25196680

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Oral, Anticoagulants, Atrial Fibrillation, Humans